Selskabets formål er at drive kommercielle aktiviteter inden for biotek, herunder udvikling af mikrober eller planter gennem en patenteret udviklingsteknologi samt enhver dertil knyttet aktivitet.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 18 mio. | -26.9 mio. | 234.5 mio. | 185.2 mio. | 25 | |
CVR: 43713523
Compared to 992 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
TRAITOMIC A/S is currently facing financial challenges, as evidenced by its declining profitability and increasing losses over the past two years. In 2024, the company reported a revenue of 18,027,000 DKK but incurred a significant loss of 26,917,000 DKK, following a revenue of 23,202,000 DKK and a loss of 20,231,000 DKK in 2023. Despite these losses, TRAITOMIC maintains a robust equity position of 185,150,000 DKK, indicating a strong capital base that could support future growth. However, the negative profit margins raise concerns about its operational efficiency and sustainability within the competitive research and development sector.
AI-generated summary
Hanne Vibeke Weywardt left the board
Carsten Sparre Conrad joined the board
Companies in the same industry and area
companydata.dk